Business Wire

For Mary Kay, It’s Mission Critical: We’ve Accelerated Our Digital Innovation Efforts to Unleash the Full Potential of Women Entrepreneurs

8.3.2023 21:32:00 EET | Business Wire | Press release

Share

Below is a statement by Deborah Gibbins, Chief Operating Officer, Mary Kay Inc., in celebration of International Women’s Day 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230308005697/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Deborah Gibbins, Mary Kay’s Chief Operating Officer (Photo courtesy: Mary Kay Inc.)

37% of women worldwide do not have access to the internet. I know - I had to read that twice, too.1

37%! The number is staggering. It feels impossible. In our always-on, always-connected world, how can more than a third of all women in the world remain “unconnected”? This shocking reality - and its implications - fuel this year’s International Women’s Day theme: “DigitALL: Innovation and technology for gender equality.”

As Chief Operating Officer at Mary Kay, I know the role technology plays in all aspects of business – especially entrepreneurial business. To maximize the opportunity offered by technology, digital literacy skills are an absolute requirement for women entrepreneurs to fully participate in our global economy. They are also a necessity for civic and social engagement.

The foundations for the Fourth Industrial Revolution are digital and they are being laid right now. For all of us this revolution holds the tremendous opportunity to leverage technology and innovation to advance women entrepreneurship and equality. The time is now to ensure women reap the benefits of this digital transformation.

The digital economy won’t wait for anyone to catch up. Women’s exclusion from the digital world has shaved $1 trillion from the gross domestic product of low- and middle-income countries in the last decade.2 Once again, change is not happening fast enough for women.

We can fix this. We must fix this.

To reach their full potential, women business owners around the world must not only have access to the digital tools we take for granted, but they must have the right skills and training to use them effectively.

That’s why bridging the digital gender gap is so personal to us at Mary Kay, a company founded by a woman for women.

Our founder, Mary Kay Ash, had a vision to offer women unmatched entrepreneurial opportunities for advancement and personal success. That means something different today than it did in the ‘60s, but that same spirit remains. As an entrepreneurship development company, our focus is lifting women entrepreneurs up and addressing the barriers they face in establishing or growing their business. Digitalization is one of them.

At Mary Kay, we are determined to put women entrepreneurs at the center of the digital transformation.

We’ve accelerated our digital innovation efforts – this includes revolutionizing Mary Kay’s Independent Beauty Consultants’ (IBCs) ability to unleash their full potential through digital upskilling, the development and roll-out of innovative digital tools, from award-winning apps featuring augmented reality (AR), to connecting IBCs with their customers in more effective and seamless ways. We’re improving not only the experience for the independent sales force, but for their customers around the world.

Here are some of the latest examples of our commitment to empower Mary Kay’s independent sales force to harness the power of digital:

  • In Europe, our award-winning “Link & Learn” is an integrated education platform comprising a robust learning curriculum IBCs can access anytime, anywhere. This self-paced, interactive learning system helps consultants put their dreams into action by providing a competency-based curriculum with relevant, expert-driven content while connecting them with a community of like-minded consultants. It includes content focused on the key areas of competency that are essential for success at each step of the career path. With this content, consultants strategically focus on key topics and acquire skills such as Selling Skills, Business Skills, Product Knowledge and Understanding the Mary Kay Way. Mary Kay has received numerous awards for this educational platform, including a coveted gold ranking in the Education category in the “2019 Spring Omni Awards.” In 2021 Mary Kay Poland received the “Innovative Company” award for the program from the Home & Market magazine, and in 2018 it was awarded a “Technology Excellence Award” from the Brandon Hall Group.
  • The InTouch® platform is a one-stop shop mobile platform which provides millions of IBCs around the world 24-hour access to information, and services to effectively manage their Mary Kay business. It includes many features to enhance their knowledge of the beauty industry through product education, basic business skills through marketing and sales tools, and a professional network. With this app, IBCs can access product ingredient information and material to share with their customers or as a quick reference.
  • The Salesforce.com platform has also recently been rolled out to our Mary Kay markets via the Mary Kay InTouch site, enabling a more seamless use of digital technology in day-to-day operations, including placing orders. IBCs receive 24/7 support from their local Mary Kay teams and save time to focus on tasks that add more value to their business.
  • Mary Kay Mirror Me™ is our real-time makeover app using augmented reality to apply makeup trends and color products for real life application. After finding their perfect look, customers can add products to their shopping bag and connect with an IBC. Mirror Me™ is available in the North America, Europe and Latin America regions.
  • Mary Kay® Skin Analyzer is a tool that brings skin care and technology together at one’s fingertips. It helps customers understand the unique characteristics of their skin and create a customized skin care routine and is available in the North America, Asia-Pacific and Latin America regions.
  • And finally, the newly launched Mary Kay Interactive Catalog brings Mary Kay catalogs to life with easy product ordering, GIFs, videos, shareable wish lists, instant augmented reality makeovers and more. The catalog is available in the North America, Europe and Latin America regions.

We also believe in digital collaborations to help women entrepreneurs harness the power of digital throughout the world. To this end, we have joined forces with:

And we’re just getting started. The digital revolution is underway. Let’s not miss out on this golden opportunity to enable women and girls to champion entrepreneurship in the digital age!

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in more than 35 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.

1 ITU (2022). Facts and Figures 2022 - The gender digital divide (itu.int)

2 UN Women. Progress on the Sustainable Development Goals. The Gender Snapshot 2022.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc.
media@mkcorp.com
+1-972-687-5332

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye